Pathology: mNSCLC - L1 - PDL1 positive; mNSCLC - L2 - PDL1 positive;
mNSCLC - L1 - PDL1 positive | mNSCLC - L2 - PDL1 positive | ||||||||
KEYNOTE-042 (PDL1>20%), 2019 | KEYNOTE-042 (PDL1>1%), 2019 | KEYNOTE-024 (PDL1>50%), 2016 | KEYNOTE-042 (PDL1>50%), 2019 | KEYNOTE-010 (P:10 mg/kg), 2016 | KEYNOTE-010 (P:10 mg/kg ; PDL1>50%), 2016 | KEYNOTE-010 (P: 2mg/kg ; PDL1>50%), 2016 | KEYNOTE-010 (P: 2mg/kg), 2016 | ||
pembrolizumab alone | 4 | T1 | T1 | T1 | T1 | ||||
pembrolizumab (10mg/kg) | 2 | T1 | T1 | ||||||
pembrolizumab (2mg/kg) | 2 | T1 | T1 | ||||||
Standard of Care (SoC) | 0 | T0 | T0 | T0 | T0 | ||||
docetaxel | 0 | T0 | T0 | T0 | T0 |